Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.48 |
| ▸ | USP30 | Q70CQ3 | 1/20 | 0.47 |
| ▸ | CHEK2 | O96017 | 2/20 | 0.45 |
| ▸ | PIK3CD | O00329 | 5/20 | 0.44 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.43 |
| ▸ | PIK3CA | P42336 | 2/20 | 0.42 |
| ▸ | PIK3CB | P42338 | 2/20 | 0.42 |
| ▸ | PIK3CG | P48736 | 2/20 | 0.42 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31270127 | 0.94 | CHEK2 (0.51) | GPR119USP30CHEK2PIK3CDHRH3 | |
| SCHEMBL31269796 | 0.94 | GPR119 (0.54) | GPR119CHEK2HRH3PDE4B | |
| SCHEMBL24117863 | 0.86 | GPR119 (0.56) | GPR119USP30CHEK2PIK3CDHRH3 | |
| SCHEMBL3342818 | 0.85 | GPR119 (0.54) | GPR119CHEK2HRH3PDE4B | |
| SCHEMBL15202720 | 0.84 | GPR119 (0.48) | GPR119USP30CHEK2PIK3CDHRH3 | |
| SCHEMBL31270177 | 0.83 | CHEK2 (0.47) | GPR119CHEK2 | |
| SCHEMBL5089073 | 0.83 | GPR119 (0.54) | GPR119USP30CHEK2PIK3CDS1PR3 | |
| SCHEMBL31269794 | 0.82 | GPR119 (0.51) | GPR119CHEK2 | |
| SCHEMBL29276820 | 0.81 | GPR119 (0.52) | GPR119USP30CHEK2PIK3CDHRH3 | |
| SCHEMBL29276822 | 0.81 | GPR119 (0.52) | GPR119USP30CHEK2PIK3CDHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | QLi5 Therapeutics AG (DE) | 2024-12-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240415819-A1 | MACROCYCLIC COMPOUNDS AS PROTEASOME SUBUNIT BETA TYPE-5 INHIBITORS | PSMB5, PSMA5, PSMB1 | GPR119 4139/4885USP30 81/4885CHEK2 3816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.